MetaVia Inc. Reports Strong Progress in Cardiometabolic Drug Development During Q2 2026

MetaVia Inc. Reports Q2 2026 Financial Results and Corporate Updates

On August 6, 2026, MetaVia Inc., a biotechnology firm specializing in cardiometabolic diseases, announced its financial results for the second quarter ended June 30, 2026. The company has made significant advancements in its clinical development programs, specifically focusing on its lead drug candidates, DA-1726 and vanoglipel (DA-1241).

Clinical Trial Achievements

MetaVia's President and CEO, Hyung Heon Kim, revealed that the company achieved a major milestone during Q2 2026. All active participants in the ongoing Phase 1 Part 3 trial of DA-1726 successfully reached the highest targeted dose levels of 48 mg and 64 mg. This accomplishment sets the stage for a crucial 16-week data readout, expected in Q4 2026. Early data from the trial indicates promising results; after eight weeks of treatment, participants experienced up to 9.1% mean weight loss, accompanied by reductions in waist circumference and improved liver function markers. These findings strengthen the confidence in DA-1726 as a potential best-in-class obesity treatment.

In addition to DA-1726, MetaVia has expanded the potential applications for vanoglipel. In June 2026, the company presented preclinical findings at the ADA 2026 Scientific Sessions. These results demonstrated that vanoglipel could have synergistic effects when combined with existing therapies for metabolic disorders, underscoring its versatility as a treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 diabetes.

Financial Overview

For the second quarter of 2026, MetaVia reported research and development expenses of approximately $3.5 million, up from about $2.3 million during the same period in 2025. This increase was largely attributed to elevated direct R&D expenses associated with the DA-1726 development program. Overall, total operating expenses for the quarter amounted to approximately $5.4 million, in comparison to $4.3 million for Q2 2025.

The company's financial results also revealed a net loss of $5.3 million, equivalent to $0.90 per share. In the prior year, a loss of $4.0 million, or $2.87 per share, was recorded based on fewer shares outstanding at that time. Despite increasing losses year-over-year, MetaVia's liquidity has remained stable, with cash and cash equivalents reaching $12.6 million as of June 30, 2026, compared to $10.3 million at the end of 2025. The company forecasts that this cash position will sustain operations throughout the remainder of 2026.

Future Goals and Anticipated Milestones

Looking ahead, MetaVia is eager to finalize the upcoming data from the crucial Phase 1 Part 3 trial of DA-1726 and plans to schedule an End-of-Phase 2 meeting with the FDA regarding the clinical pathway for vanoglipel. By continuing to develop its innovative treatments, MetaVia aims to establish itself as a transformative player in cardiometabolic healthcare. As they move forward, the convergence of promising research results and strategic planning positions them well for future growth and potential breakthroughs in the treatment of obesity and related metabolic disorders.

MetaVia Inc. is committed to its mission to change the landscape of cardiometabolic diseases through groundbreaking research and development. The ongoing advancements signal a hopeful outlook for patients and shareholders alike as the company leapfrogs into the second half of 2026.